Emunamedica Awarded Category III Reimbursement Coding By CPT-AMA Committee

Novel chronic wound diagnostics company Emunamedica LLC was awarded a Category III reimbursement code recently which will go into affect January 1, 2018. The code is effective for a five year period and covers “Near-infrared spectroscopy studies of lower extremity wounds (eg, for oxyhemoglobin measurement)” under code number 0493T. The code is specific for Emunamedica’s patented predictive wound diagnostic system which will enable the company to track usage of its device in the field.

Chronic wounds affect over 8 million people in the United States and many millions more worldwide. Currently there are no accurate predictive wound diagnostics available to clinicians for chronic wounds. The current standard of care is to measure wound size, which has been shown in multiple published studies to have a predictive power of just over 50%. Emunamedica’s technology has been shown in clinical studies to have a predictive power of over 80% and can be utilized in just a few minutes.

“I am very proud of our team. This is a great achievement considering that few, if any devices receive a Category III CPT code prior to FDA clearance. This speaks to the significant need for better diagnostics in the field of chronic wounds” said David Kolb, Chairman and Co-Founder of Emunamedica.